Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
Go back to Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury| ORAGENICS (NYSE: OGEN) | Delayed: 0.58 +0.03 (5.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.55 | 52 Week High | $2.12 | |||
| Open | $0.57 | 52 Week Low | $0.33 | |||
| Day High | $0.61 | P/E | N/A | |||
| Day Low | $0.56 | EPS | $-0.45 | |||
| Volume | 70,940 | |||||
